NOVATO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Raptor
Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today announced that
senior management will present a corporate overview and clinical pipeline
updates at two upcoming healthcare investor conferences:
-- The 7th Annual BIO Investor Forum, to be held October 29-31, 2008 at the
Palace Hotel in San Francisco, CA. Raptor's presentation will take
place on Wednesday, October 29 at 4:45pm ET (1:45pm PT) in Telegraph
Hill. A live audio webcast of the presentation will be available at
-- The Rodman & Renshaw 10th Annual Healthcare Conference, to be held
November 10-12, 2008 at New York Palace Hotel in New York, NY.
Raptor's presentation will take place on Tuesday, November 11 at
9:30am ET (6:30am PT) in Holmes II (4th floor). A live audio webcast of
the presentation will be available at
Both webcasts will be archived for 30 days and accessible through the investor relations section of Raptor's website at http://www.raptorpharma.com.
For more information on BIO Investor Forum conference please visit: http://investorforum.bio.org/opencms/bif/2008/
For more information on Rodman & Renshaw's 10th Annual Healthcare Conference please visit: http://www.rodmanandrenshaw.com/conferences
About Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. ("Raptor") is a publicly traded biotechnology company dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it believes it may have the greatest impact. Raptor is involved in clinical development of its proprietary Delayed-Release Cysteamine ("DR Cysteamine") product candidate in nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease and Batten Disease, and its ConviviaTM product candidate in aldehyde dehydrogenase ("ALDH2") deficiency. In its preclinical programs Raptor bioengineers novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins which are designed to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTideTM, WntTideTM and NeuroTransTM.
For additional information, please visit http://www.raptorpharma.com.
FORWARD LOOKING STATEMENTS
This document contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements relate to future events or our future results of operation or
future financial performance, including, but not limited to the following
statements: Raptor's ability to develop any of its preclinical and clinical
drug product candidates. These statements are only predictions and involve
known and unknown risks, uncertainties and other factors, which may cause
our actual results to be materially different from these forward-looking
statements. Factors which may significantly change or prevent our forward
looking statements from fruition include that we may be unsuccessful in
developing any products or acquiring products; that our technology may not
be validated as we progress further and our methods may not be accepted by
the scientific community; that we are unable to retain or attract key
employees whose knowledge is essential to the development of our products;
that unforeseen scientific difficulties develop with our process; that our
patents are not sufficient to protect essential aspects of our technology;
that competitors may invent better technology; that our products may not
work as well as hoped or worse, that our products may harm recipients; and
that we may not be able to raise sufficient funds for development or
working capital when we require it. As well, our products may never develop
into useful products and even if they do, they may not be approved for sale
to the public. We caution readers not to place undue reliance on any such
forward-looking statements, which speak only as of the date they were made.
Certain of these risks, uncertainties, and other factors are described in
greater detail in our filings from time to time with the Securities and
Exchange Commission (the "SEC"), which we strongly urge you to read and
consider, including our Registration Statement on Form S-1 that was
declared effective on August 7, 2008; our annual report on Form 10-KSB
filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the
SEC on July 9, 2008, all of which are available free of charge on the SEC's
web site at http://www.sec.gov. Subsequent written and oral forward-looking
statements attributable to us or to persons acting on our behalf are
expressly qualified in their entirety by the cautionary statements set
forth in our reports filed with the SEC. We expressly disclaim any intent
or obligation to update any forward-looking statements.
For more information, please contact:
The Ruth Group
Sara Ephraim (investors)
Janine McCargo (media)
|SOURCE Raptor Pharmaceuticals Corp.|
Copyright©2008 PR Newswire.
All rights reserved